Timberlyne Therapeutics is a biopharmaceutical company that develops therapies for autoimmune diseases.
Timberlyne Therapeutics has raised $180.0M in total funding. The most recent round was Series A. The last funding was announced in January 2025.
Timberlyne Therapeutics's investors include Lilly Asia Ventures, Abingworth, Bain Capital Life Sciences, 3H Health Investment, Venrock Healthcare Capital Partners.
Timberlyne Therapeutics is headquartered in San Diego, United States.
Timberlyne Therapeutics is a biopharmaceutical company that develops therapies for autoimmune diseases.
Timberlyne Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Timberlyne Therapeutics — Funding & Investors." VCBacked, January 9, 2025, https://www.vcbacked.co/company/timberlyne-therapeutics. Accessed October 29, 2026.
VCBacked. (2025). Timberlyne Therapeutics — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/timberlyne-therapeutics
{{cite web |title=Timberlyne Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/timberlyne-therapeutics |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated